<p>拥有大量资金的投资者对 <strong>再生元制药</strong> (NASDAQ: REGN) 持乐观态度。</p>
<p>而散户交易者应该知道这一点。</p>
<p>我们今天注意到这一点，当这些头寸出现在我们在 Benzinga 跟踪的公开可用期权历史中。</p>
<p>我们不知道这些是机构还是仅仅是富有的个人。但当 REGN 发生如此重大的事情时，通常意味着有人知道即将发生什么。</p>
<p>今天，Benzinga 的期权扫描仪发现了 13 笔 <strong>再生元制药</strong> 的期权交易。</p>
<p>这并不正常。</p>
<p>这些大资金交易者的整体情绪在 38% 看涨和 30% 看跌之间分裂。</p>
<p>在我们发现的所有期权中，有 1 笔看跌期权，总金额为 56,100 美元，以及 12 笔看涨期权，总金额为 540,338 美元。</p>
<h3>价格目标是什么？</h3>
<p>在评估交易量和未平仓合约后，很明显主要市场参与者正关注 <strong>再生元制药</strong> 的价格区间在 400.0 美元到 1000.0 美元之间，涵盖了过去三个月。</p>
<h3>交易量与未平仓合约的洞察</h3>
<p>查看交易量和未平仓合约是交易期权时的一个强大举措。这些数据可以帮助您跟踪 <strong>再生元制药</strong> 在特定行权价格的期权流动性和兴趣。下面，我们可以观察到过去 30 天内所有 <strong>再生元制药</strong> 的鲸鱼交易在 400.0 美元到 1000.0 美元的行权价格范围内的交易量和未平仓合约的演变。</p>
<h3>再生元制药过去 30 天的期权交易量和未平仓合约</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期权看涨图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png"/></p>
<h3>检测到的重要期权交易：</h3>
<table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行权价格</strong></th>
<th><strong>总交易价格</strong></th>
<th align="right"><strong>未平仓合约</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>中性</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看涨</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看跌</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
<h3>关于再生元制药</h3>
<p>再生元制药发现、开发和商业化用于治疗眼病、心血管疾病、癌症和炎症的产品。该公司有多个已上市产品，包括用于湿性年龄相关性黄斑变性和其他眼病的低剂量 Eylea 和 Eylea HD；在免疫学领域的 Dupixent；用于降低 LDL 胆固醇的 Praluent；在肿瘤学领域的 Libtayo；以及在类风湿关节炎领域的 Kevzara。再生元还与赛诺菲及其他合作伙伴独立开发单克隆抗体和双特异性抗体，并拥有早期阶段的合作伙伴关系，将新技术引入管道，包括 RNAi（Alnylam）和基于 Crispr 的基因编辑（Intellia）。</p>
<p>在对围绕再生元制药的期权交易进行彻底审查后，我们将更详细地审视该公司。这包括对其当前市场状态和表现的评估。</p>
<h3>再生元制药的当前市场地位</h3>
<ul>
<li>目前交易量为 246,591，REGN 的价格下跌了 -0.17%，现为 778.0 美元。</li>
<li>RSI 指标显示该股票可能接近超买状态。</li>
<li>预计收益发布将在 42 天后。</li>
</ul>
<h3>再生元制药的专业分析师评级</h3>
<p>在过去 30 天内，共有 5 位专业分析师对该股票进行了评估，设定的平均价格目标为 786.2 美元。</p>
<p><strong>检测到异常期权活动：聪明资金在行动</strong></p>
<p>Benzinga Edge 的异常期权板块在潜在市场动向发生之前发现可能的市场推动者。查看大资金在您喜欢的股票上采取了什么头寸。点击这里访问。
* 反映出担忧，Truist Securities 的一位分析师将其评级下调至买入，新的价格目标为 798 美元。
* 在评估中保持一致，Scotiabank 的一位分析师对再生元制药保持行业表现评级，目标价格为 770 美元。
* Wells Fargo 的一位分析师继续对再生元制药保持等权重评级，目标价格为 745 美元。
* BMO Capital 的一位分析师继续对再生元制药保持跑赢大盘评级，目标价格为 850 美元。
* 摩根士丹利的一位分析师继续对再生元制药保持等权重评级，目标价格为 768 美元。</p>
<p>期权交易存在更高的风险和潜在的回报。精明的交易者通过不断学习、调整策略、监控多个指标以及密切关注市场动态来管理这些风险。通过来自 Benzinga Pro 的实时警报，随时了解最新的再生元制药期权交易。</p>

再生元制药

<p>投资者对再生元制药表现出兴趣，检测到显著的期权活动。市场情绪混合，38% 看涨，30% 看跌。主要市场动向集中在 400 美元到 1000 美元的价格区间。分析师的评级各不相同，价格目标范围在 745 美元到 850 美元之间。该股票目前交易价格为 778 美元，下跌 0.17%。期权交易带来更高的风险和回报，需要仔细监控和策略调整</p>

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Regeneron Pharmaceuticals</strong> (NASDAQ: REGN).</p>
<div class="lb-trans"><p>拥有大量资金的投资者对 <strong>再生元制药</strong> (NASDAQ: REGN) 持乐观态度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者应该知道这一点。</p>
</div><p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我们今天注意到这一点，当这些头寸出现在我们在 Benzinga 跟踪的公开可用期权历史中。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>我们不知道这些是机构还是仅仅是富有的个人。但当 REGN 发生如此重大的事情时，通常意味着有人知道即将发生什么。</p>
</div><p>Today, Benzinga's options scanner spotted 13 options trades for <strong>Regeneron Pharmaceuticals</strong>.</p>
<div class="lb-trans"><p>今天，Benzinga 的期权扫描仪发现了 13 笔 <strong>再生元制药</strong> 的期权交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>这并不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 38% bullish and 30%, bearish.</p>
<div class="lb-trans"><p>这些大资金交易者的整体情绪在 38% 看涨和 30% 看跌之间分裂。</p>
</div><p>Out of all of the options we uncovered, there was 1 put, for a total amount of $56,100, and 12, calls, for a total amount of $540,338.</p>
<div class="lb-trans"><p>在我们发现的所有期权中，有 1 笔看跌期权，总金额为 56,100 美元，以及 12 笔看涨期权，总金额为 540,338 美元。</p>
</div><h3>What's The Price Target?</h3>
<div class="lb-trans"><h3>价格目标是什么？</h3>
</div><p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $400.0 and $1000.0 for Regeneron Pharmaceuticals, spanning the last three months.</p>
<div class="lb-trans"><p>在评估交易量和未平仓合约后，很明显主要市场参与者正关注 <strong>再生元制药</strong> 的价格区间在 400.0 美元到 1000.0 美元之间，涵盖了过去三个月。</p>
</div><h3>Insights into Volume &amp; Open Interest</h3>
<div class="lb-trans"><h3>交易量与未平仓合约的洞察</h3>
</div><p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale trades within a strike price range from $400.0 to $1000.0 in the last 30 days.</p>
<div class="lb-trans"><p>查看交易量和未平仓合约是交易期权时的一个强大举措。这些数据可以帮助您跟踪 <strong>再生元制药</strong> 在特定行权价格的期权流动性和兴趣。下面，我们可以观察到过去 30 天内所有 <strong>再生元制药</strong> 的鲸鱼交易在 400.0 美元到 1000.0 美元的行权价格范围内的交易量和未平仓合约的演变。</p>
</div><h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<div class="lb-trans"><h3>再生元制药过去 30 天的期权交易量和未平仓合约</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2025/1766512900_0.png"/></p>
<h3>Significant Options Trades Detected:</h3>
<div class="lb-trans"><h3>检测到的重要期权交易：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行权价格</strong></th>
<th><strong>总交易价格</strong></th>
<th align="right"><strong>未平仓合约</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>中性</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看涨</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看跌</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
</div><h3>About Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>关于再生元制药</h3>
</div><p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<div class="lb-trans"><p>再生元制药发现、开发和商业化用于治疗眼病、心血管疾病、癌症和炎症的产品。该公司有多个已上市产品，包括用于湿性年龄相关性黄斑变性和其他眼病的低剂量 Eylea 和 Eylea HD；在免疫学领域的 Dupixent；用于降低 LDL 胆固醇的 Praluent；在肿瘤学领域的 Libtayo；以及在类风湿关节炎领域的 Kevzara。再生元还与赛诺菲及其他合作伙伴独立开发单克隆抗体和双特异性抗体，并拥有早期阶段的合作伙伴关系，将新技术引入管道，包括 RNAi（Alnylam）和基于 Crispr 的基因编辑（Intellia）。</p>
</div><p>After a thorough review of the options trading surrounding Regeneron Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<div class="lb-trans"><p>在对围绕再生元制药的期权交易进行彻底审查后，我们将更详细地审视该公司。这包括对其当前市场状态和表现的评估。</p>
</div><h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>再生元制药的当前市场地位</h3>
</div><ul>
<li>Currently trading with a volume of 246,591, the REGN's price is down by -0.17%, now at $778.0.</li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量为 246,591，REGN 的价格下跌了 -0.17%，现为 778.0 美元。</li>
<li>RSI 指标显示该股票可能接近超买状态。</li>
<li>预计收益发布将在 42 天后。</li>
</ul>
</div><h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>再生元制药的专业分析师评级</h3>
</div><p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $786.2.</p>
<div class="lb-trans"><p>在过去 30 天内，共有 5 位专业分析师对该股票进行了评估，设定的平均价格目标为 786.2 美元。</p>
</div><p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<div class="lb-trans"><p><strong>检测到异常期权活动：聪明资金在行动</strong></p>
</div><p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $798.
* Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Perform rating on Regeneron Pharmaceuticals with a target price of $770.
* An analyst from Wells Fargo persists with their Equal-Weight rating on Regeneron Pharmaceuticals, maintaining a target price of $745.
* Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $850.
* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Regeneron Pharmaceuticals, targeting a price of $768.</p>
<div class="lb-trans"><p>Benzinga Edge 的异常期权板块在潜在市场动向发生之前发现可能的市场推动者。查看大资金在您喜欢的股票上采取了什么头寸。点击这里访问。
* 反映出担忧，Truist Securities 的一位分析师将其评级下调至买入，新的价格目标为 798 美元。
* 在评估中保持一致，Scotiabank 的一位分析师对再生元制药保持行业表现评级，目标价格为 770 美元。
* Wells Fargo 的一位分析师继续对再生元制药保持等权重评级，目标价格为 745 美元。
* BMO Capital 的一位分析师继续对再生元制药保持跑赢大盘评级，目标价格为 850 美元。
* 摩根士丹利的一位分析师继续对再生元制药保持等权重评级，目标价格为 768 美元。</p>
</div><p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.</p>
<div class="lb-trans"><p>期权交易存在更高的风险和潜在的回报。精明的交易者通过不断学习、调整策略、监控多个指标以及密切关注市场动态来管理这些风险。通过来自 Benzinga Pro 的实时警报，随时了解最新的再生元制药期权交易。</p>
</div>

再生元制药的期权狂潮：你需要了解的内容